{"filing":{"accession_number":"0001493152-26-027837","cik":"0001412486","ticker":"COCP","company_name":"Cocrystal Pharma, Inc.","form":"8-K","filing_date":"2026-06-09","report_date":null,"primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315226027837/form8-k.htm"},"events":[{"id":6011,"run_id":5276,"accession_number":"0001493152-26-027837","anchor_item_number":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The filing discloses the appointment of James Sapirstein as Chief Executive Officer of Cocrystal Pharma, effective June 3, 2026. While the disclosure also includes compensatory arrangements (base salary of $265,000, performance bonus, and stock option grants), the principal disclosed action is the appointment of a new CEO to replace co-CEOs Sam Lee and James Martin. This is a material executive change affecting the company's leadership structure.","company_name":"Cocrystal Pharma, Inc.","ticker":"COCP","filing_date":"2026-06-09","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":5391,"accession_number":"0001493152-26-027837","item_number":null,"item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of James Sapirstein as Chief Executive Officer of Cocrystal Pharma, effective June 3, 2026. While the disclosure also includes compensatory arrangements (base salary of $265,000, performance bonus, and stock option grants), the principal disclosed action is the appointment of a new CEO to replace co-CEOs Sam Lee and James Martin. This is a material executive change affecting the company's leadership structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-09T11:01:05.910603+00:00","company_name":"Cocrystal Pharma, Inc.","ticker":"COCP","filing_date":"2026-06-09"}]}